ClinicalTrials.gg
CompletedNCT06886269Updated Jun 18, 2025

A Study to Evaluate How the Body Processes 14C-VX-993 After a Single Oral Dose

A Phase 1 interventional study of 14C-VX-993 in Pain, sponsored by Vertex Pharmaceuticals Incorporated. Completed at 1 site in United States. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-06-18.

Sponsored by Vertex Pharmaceuticals Incorporated · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was May 2025, 1 year 6 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
8
Allocation
Not applicable
Ages
18 Years to 55 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 26 studies in Pain by Vertex Pharmaceuticals Incorporated — none open to participants now, none under way, none of them phase 3. Pain · Vertex Pharmaceuticals Incorporated.

Enrollment
26th of 26
8 · median 39
Started
2025
with 2 others
Phase 1
24 of 26
none open now
Registered
23rd of 26
by date

Among the 26 studies in Pain by Vertex Pharmaceuticals Incorporated, this one is the 26th largest by enrollment, is one of 3 that started in 2025, is one of 24 in phase 1, and was the 23rd registered.

Pain

10,069 studies on the registry are indexed under Pain; 1,650 are open to participants now.

Browse Pain studies →

Open to participants now

None of the 26 studies in Pain by Vertex Pharmaceuticals Incorporated is open now. The open studies under Pain, anywhere →

Who these studies take

Of the 927 Pain studies recruiting now, 382 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 221 take healthy volunteers.

This study: 18 Years to 55 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 26 studies in Pain by Vertex Pharmaceuticals Incorporated as a file.
02

Study summary

The purpose of the study is to evaluate the routes and rate of elimination and recovery of total radioactivity (TRA) and characterize the Pharmacokinetic (PK) of VX-993 after a single oral dose of 14C-VX-993.

Read the detailed description

This clinical trial information was submitted voluntarily under the applicable law and, therefore, certain submission deadlines may not apply. (That is, clinical trial information for this applicable clinical trial was submitted under section 402(j)(4)(A) of the Public Health Service Act and 42 CFR 11.60 and is not subject to the deadlines established by sections 402(j)(2) and (3) of the Public Health Service Act or 42 CFR 11.24 and 11.44.)

03

Conditions studied

  • Pain

Browse trials for

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Eligibility criteria

Key Inclusion Criteria:

  • (BMI) of 18.0 to 32.0 kilogram per meter square (kg/m\^2), inclusive
  • A total body weight of more than (>) 50 kg
  • Participants must have at least 1 regular bowel movement per day

Key Exclusion Criteria:

  • History of febrile illness or other acute illness that has not fully resolved within 14 days before the first dose of study drug
  • Any condition possibly affecting drug absorption, distribution, metabolism, or excretion
  • Exposure to any non-environmental radiation within 12 months of dosing
  • Participation in more than 1 radiolabeled study (if prior radiation exposure unknown) or participation in more than 3 radiolabeled studies (if radiation exposure known) in the 12 months before dosing or if the annual whole body radiation exposure from previous studies (including this dosing) exceeds FDA-allowed maximum whole body radiation exposure of 5000 mrem

Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
8 participants (actual)

Study arms

  • Experimental
    14C VX-993

    Participants will receive a single oral dose of 14C-VX-993 after an overnight fast of at least 8 hours.

    Drug: 14C-VX-993

Interventions

  • Drug14C-VX-993

    Solution for Oral Administration.

06

What researchers measure

Primary outcomes

  1. Terminal Phase Rate Constant (λz) of VX-993 in Plasma

    Time frame: From Day 1 up to Day 25

  2. Area Under the Concentration Versus Time Curve From the Time of Dosing to the Last Measurable Concentration (AUC0-tlast) of VX-993 in Plasma

    Time frame: From Day 1 up to Day 25

  3. Area Under the Concentration Versus Time Curve From the Time of Dosing Extrapolated to Infinity (AUC0-inf) of VX-993 in Plasma

    Time frame: From Day 1 up to Day 25

  4. Apparent Clearance (CL/F) of VX-993 in Plasma

    Time frame: From Day 1 up to Day 25

  5. Maximum Observed Plasma Concentration (Cmax) of VX-993 in Plasma

    Time frame: From Day 1 up to Day 25

  6. Time for VX-993 to Reach Maximum Concentration (Tmax) in Plasma

    Time frame: From Day 1 up to Day 25

  7. Apparent Volume of Distribution (Vz/F) (Based on the Terminal Phase) of VX-993 in Plasma

    Time frame: From Day 1 up to Day 25

  8. Terminal Phase Rate Constant (λz) of Total Radioactivity (TRA) in Whole blood and Plasma

    Time frame: From Day 1 up to Day 25

  9. Amount of Radioactivity Excreted (Ae) of TRA in Urine, Feces and Vomitus (if applicable)

    Time frame: Pre dose up to Day 25

  10. AUC0-tlast of TRA in Whole blood and Plasma

    Time frame: From Day 1 up to Day 25

  11. AUC0-inf of TRA in Whole blood and Plasma

    Time frame: From Day 1 up to Day 25

  12. CL/F of TRA in Whole blood and Plasma

    Time frame: From Day 1 up to Day 25

  13. Renal Clearance (CLr) of TRA in Urine and Feces

    Time frame: Pre dose up to Day 25

  14. Cmax of TRA in Whole blood and Plasma

    Time frame: From Day 1 up to Day 25

  15. Fraction (percent) of Dose Excreted Unchanged in Urine of TRA

    Time frame: Pre dose up to Day 25

  16. Tmax of TRA in Whole blood and Plasma

    Time frame: From Day 1 up to Day 25

  17. Apparent Volume of Distribution (Based on the Terminal Phase) of TRA in Whole blood and Plasma

    Time frame: From Day 1 up to Day 25

  18. Amount of VX-993 and Metabolites, Expressed as a percent of TRA, in Plasma, Urine and Feces

    Time frame: From Day 1 up to Day 25

Secondary outcomes

  1. Metabolite Profiling and Identification in Plasma, Urine, and Feces

    Time frame: From Day 1 up to Day 25

  2. Terminal Phase Rate Constant (λz) of VX-993 Metabolites in Plasma and Urine (if applicable)

    Time frame: From Day 1 up to Day 25

  3. Amount of radioactivity excreted (Ae) of VX-993 Metabolites in Urine and Feces

    Time frame: Pre dose up to Day 25

  4. AUC0-last of VX-993 Metabolites in Plasma

    Time frame: From Day 1 up to Day 25

  5. AUC0-inf of VX-993 Metabolites in Plasma

    Time frame: From Day 1 up to Day 25

  6. CL/F of VX-993 Metabolites in Plasma

    Time frame: From Day 1 up to Day 25

  7. CLr of VX-993 Metabolites in Urine

    Time frame: From Day 1 up to Day 25

  8. Cmax of VX-993 Metabolites in Plasma

    Time frame: From Day 1 up to Day 25

  9. Fraction (percent) of Dose Excreted Unchanged in Urine of VX-993 Metabolites

    Time frame: Pre dose up to Day 25

  10. Tmax of VX-993 Metabolites in Plasma

    Time frame: Day 1 up to Day 25

  11. Apparent Volume of Distribution (Based on the Terminal Phase) of VX-993 Metabolites in Plasma

    Time frame: Day 1 up to Day 25

  12. Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

    Time frame: Day 1 up to Day 35

  13. Safety and Tolerability as Assessed by Number of Participants With Clinically Meaningful Findings in Columbia Suicide Severity Rating Scale (C-SSRS) Responses

    Time frame: Pre-dose up to Day 35

07

Study locations

1 site
  • Celerion - Lincoln
    Lincoln, Nebraska 68502, United States
08

References and documents

Individual participant data

Plan to share: No — Details on Vertex data sharing criteria and process for requesting access can be found at: https://www.vrtx.com/independent-research/clinical-trial-data-sharing

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2025 to primary completion in May 2025, 1 month.

Of 104 industry-sponsored phase 1 interventional studies under Pain, half reached primary completion within 4 months of starting (the median), counting those still running; a quarter within 1 and three quarters within 9. This study's 1 month is below that.

Counting every sponsor, half of 220 studies reached it within 9 months; a quarter within 3 and three quarters within 29.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 14, 2025
First posted
Mar 20, 2025
StartActual
Mar 21, 2025
Primary completionActual
May 17, 2025
CompletionActual
May 17, 2025
Last update
Jun 18, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 18, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06886269
Responsible party
Sponsor
First posted
Mar 20, 2025
Start date
Mar 21, 2025
Primary completion
May 17, 2025
Completion
May 17, 2025
Last update
Jun 18, 2025

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion